Lonza completes acquisition of InterHealth Nutraceuticals

The combination of the two businesses allows Lonza to offer InterHealth’s more than 15 branded ingredients, including its cornerstone ingredient, UC-II, which is revolutionizing the joint-health segment.

The InterHealth business will become part of Lonza’s Consumer Care Business Unit, but will retain its facilities and employees. The combination of the two businesses allows Lonza to offer InterHealth’s more than 15 branded ingredients, including its cornerstone ingredient, UC-II, which is revolutionizing the joint-health segment.

“We are looking forward to welcoming the highly capable team to our Lonza family. They nicely complement our offerings and will be joining us in our quest to becoming the world’s leading and most-trusted supplier to the pharmaceutical, biotech and specialty ingredients markets.” said Richard Ridinger, Lonza’s Chief Executive Officer. “Lonza will be able to harness the proven management and branding capabilities and leverage them to a global level.”

Lonza acquired InterHealth for a total transaction price of up to USD 300 million split into an upfront payment and an earn-out payment. The transaction is expected to be immediately accretive to Lonza’s earnings.